New drug with chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called NRT6008 combined with standard chemotherapy for pancreatic cancer that cannot be surgically removed. The goal is to see if adding this new drug makes the chemotherapy work better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with pancreatic cancer (ductal adenocarcinoma type) confirmed by biopsy or tissue sample
- Cancer is locally advanced and cannot be surgically removed, but has not spread to distant organs
- Able to perform light activities (ECOG score of 0–1), with a life expectancy of at least 3 months
- Have not received any prior cancer treatment (chemotherapy, radiation, targeted therapy, or immunotherapy)
- Adequate organ function: normal kidney, liver, bone marrow, and blood clotting levels
- Women of childbearing potential must have a negative pregnancy test and commit to contraception for 12 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a new treatment for people with advanced pancreatic cancer that has spread and is not removable by surgery, after standard treatments like chemotherapy no longer work. The goal is to see if this experimental therapy can help shrink tumors or slow the disease.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Unresectable Locally Advanced Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.